José A. Hidalgo

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · The Lancet · 2018 · 371 citations · Full text

Hiv/aids Counselling, Treatment And Prevention, Week 48 +14

Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial

Michael Aboud, Richard Kaplan, Johannes Lombaard et al. · The Lancet Infectious Diseases · 2019 · 190 citations

First-line Therapy, Human Retrovirus, Immunology +9

Risk of cancers during interrupted antiretroviral therapy in the SMART study

Michael J. Silverberg, Jacqueline Neuhaus, Mark Bower et al. · AIDS · 2007 · 136 citations

Submandibular gland needle biopsy for the diagnosis of Parkinson disease

Charles H. Adler, Brittany N. Dugger, Michael L. Hinni et al. · Neurology · 2014 · 130 citations · Full text

Submandibular Gland Biopsy for the Diagnosis of Parkinson Disease

Thomas G. Beach, Charles H. Adler, Brittany N. Dugger et al. · Journal of Neuropathology & Experimental Neurology · 2013 · 114 citations · Full text

Corticobasal Degeneration, Clinical Neurology, Diagnosis +17